Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix

Biochemical Journal

Volumn 473, Issue 11, 2016, Pages 1579-1591

  Leroy, Emilie ^a,b   Dusa, Alexandra ^a,b   Colau, Didier ^a   Motamedi, Amir ^c   Cahu, Xavier ^a,b   Mouton, Céline ^a,b   Huang, Lily J ^d   Shiau, Andrew K ^c   Constantinescu, Stefan N ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Inhibitor; JAK STAT signalling; JAK2 V617F; Kinase; Myeloproliferative neoplasm (MPN)

Indexed keywords

ARGININE; INTERLEUKIN 3; JANUS KINASE; JANUS KINASE 2; JANUS KINASE HOMOLOGY 2; LYSINE; STAT5 PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; JAK2 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXON; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MUTAGENESIS; MYELOPROLIFERATIVE NEOPLASM; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; JANUS KINASE 2; MUTATION; PHOSPHORYLATION; PROTEIN DOMAINS;

EID: 84975109095     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BCJ20160085     Document Type: Article

References (49)

1. Akada, H., Akada, S., Hutchison, R.E., Sakamoto, K., Wagner, K.U. and Mohi, G. (2014) Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells 32, 1878-1889
2. Ghoreschi, K., Laurence, A. and O'Shea, J.J. (2009) Janus kinases in immune cell signaling. Immunol. Rev. 228, 273-287
3. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061
5. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. and Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
6. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397
7. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T. et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799-807
8. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L. et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787-798
9. Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R. et al. (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426-435
10. Saharinen, P. and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963
11. Shan, Y., Gnanasambandan, K., Ungureanu, D., Kim, E.T., Hammaren, H., Yamashita, K., Silvennoinen, O., Shaw, D.E. and Hubbard, S.R. (2014) Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. Nat. Struct. Mol. Biol. 21, 579-584
12. Lupardus, P.J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A.R. and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030
13. Brooks, A.J., Dai, W., O'Mara, M.L., Abankwa, D., Chhabra, Y., Pelekanos, R.A., Gardon, O., Tunny, K.A., Blucher, K.M., Morton, C.J. et al. (2014) Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344, 1249783
14. Varghese Leila, N., Ungureanu, D., Liau Nicholas, P.D., Young Samuel, N., Laktyushin, A., Hammaren, H., Lucet, I.S., Nicola, N.A., Silvennoinen, O., Babon, J.J. and Murphy, J.M. (2014) Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. Biochem. J. 458, 395-405
15. Springuel, L., Hornakova, T., Losdyck, E., Lambert, F., Leroy, E., Constantinescu, S.N., Flex, E., Tartaglia, M., Knoops, L. and Renauld, J.C. (2014) Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood 124, 3924-3931
16. Bandaranayake, R.M., Ungureanu, D., Shan, Y., Shaw, D.E., Silvennoinen, O. and Hubbard, S.R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
17. Lucet, I.S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S.E., Walter, M., Burns, C.J., Treutlein, H., Wilks, A.F. and Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183
18. Kulagowski, J.J., Blair, W., Bull, R.J., Chang, C., Deshmukh, G., Dyke, H.J., Eigenbrot, C., Ghilardi, N., Gibbons, P., Harrison, T.K. et al. (2012) Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. J. Med. Chem. 55, 5901-5921
19. Toms, A.V., Deshpande, A., McNally, R., Jeong, Y., Rogers, J.M., Kim, C.U., Gruner, S.M., Ficarro, S.B., Marto, J.A., Sattler, M. et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221-1223
20. Wallweber, H.J., Tam, C., Franke, Y., Starovasnik, M.A. and Lupardus, P.J. (2014) Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2. Nat. Struct.Mol.Biol.21, 443-448
21. Dusa, A., Mouton, C., Pecquet, C. and Herman, M. (2010) Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 5, e11157
22. Zhao, L., Dong, H., Zhang, C.C., Kinch, L., Osawa, M., Iacovino, M., Grishin, N.V., Kyba, M. and Huang, L.J. (2009) A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J. Biol. Chem. 284, 26988-26998
23. Sanz Sanz, A., Niranjan, Y., Hammaren, H., Ungureanu, D., Ruijtenbeek, R., Touw, I.P., Silvennoinen, O. and Hilhorst, R. (2014) The JH2 domain and SH2-JH2 linker regulate JAK2 activity: a detailed kinetic analysis of wild type and V617F mutant kinase domains. Biochim. Biophys. Acta 1844, 1835-1841
24. Liu, X., Constantinescu, S.N., Sun, Y., Bogan, J.S., Hirsch, D., Weinberg, R.A. and Lodish, H.F. (2000) Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal. Biochem. 280, 20-28
25. Kohlhuber, F., Rogers, N.C., Watling, D., Feng, J., Guschin, D., Briscoe, J., Witthuhn, B.A., Kotenko, S.V., Pestka, S., Stark, G.R. et al. (1997) A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol. Cell. Biol. 17, 695-706
26. Pellegrini, S., John, J., Shearer, M., Kerr, I.M. and Stark, G.R. (1989) Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol. Cell. Biol. 9, 4605-4612
27. Velazquez, L., Fellous, M., Stark, G.R. and Pellegrini, S. (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70, 313-322
28. Muller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A.G., Barbieri, G., Witthuhn, B.A., Schindler, C. et al. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366, 129-135
29. Seubert, N., Royer, Y., Staerk, J., Kubatzky, K.F., Moucadel, V., Krishnakumar, S., Smith, S.O. and Constantinescu, S.N. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12, 1239-1250
30. Sliva, D., Wood, T.J., Schindler, C., Lobie, P.E. and Norstedt, G. (1994) Growth hormone specifically regulates serine protease inhibitor gene transcription via gamma-activated sequence-like DNA elements. J. Biol. Chem. 269, 26208-26214
31. Kabsch, W. (2010) Xds. Acta Crystallogr. D Biol. Crystallogr. 66 (Pt 2), 125-132
32. Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A. et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67 (Pt 4), 235-242
33. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and Read, R.J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40 (Pt 4), 658-674
34. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W. et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66 (Pt 2), 213-221
35. Müller, K., Amman, H.J., Doran, D.M., Gerber, P.R., Gubernator, K. and Schrepfer, G. (1988) MOLOC: a molecular modeling program. Bull. Soc. Chim. Belg. 97, 655-667
36. Gnanasambandan, K., Magis, A. and Sayeski, P.P. (2010) The constitutive activation of Jak2-V617F is mediated by a pi stacking mechanism involving phenylalanines 595 and 617. Biochemistry 49, 9972-9984
37. Staerk, J., Kallin, A., Demoulin, J-B., Vainchenker, W. and Constantinescu, S.N. (2005) JAK1 and Tyk2 activation by the homologous Polycythemia Vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280, 41893-41899
38. Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grotzinger, J., Wollmer, A., Zhong, Z., Darnell. Jr, J.E., Graeve, L. et al. (1996) Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271, 12999-13007
39. Eyckerman, S., Waelput, W., Verhee, A., Broekaert, D., Vandekerckhove, J. and Tavernier, J. (1999) Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line. Eur. Cytokine Netw. 10, 549-556
40. Jeong, E.G., Kim, M.S., Nam, H.K., Min, C.K., Lee, S., Chung, Y.J., Yoo, N.J. and Lee, S.H. (2008) Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 14, 3716-3721
41. Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F. et al. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751-758
42. Ma, W., Kantarjian, H., Zhang, X., Yeh, C.H., Zhang, Z.J., Verstovsek, S and Albitar, M. (2009) Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J. Mol. Diagn. 11, 49-53
43. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G. and Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. U.S.A. 102, 18962-18967
44. Lu, X., Huang, L.J. and Lodish, H.F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266
45. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468
46. Mercher, T., Wernig, G., Moore, S.A., Levine, R.L., Gu, T.L., Frohling, S., Cullen, D., Polakiewicz, R.D., Bernard, O.A., Boggon, T.J. et al. (2006) JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108, 2770-2779
47. Mullighan, C.G., Zhang, J., Harvey, R.C., Collins-Underwood, J.R., Schulman, B.A., Phillips, L.A., Tasian, S.K., Loh, M.L., Su, X., Liu, W. et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 9414-9418
48. Constantinescu, S.N., Leroy, E., Gryshkova, V., Pecquet, C. and Dusa, A. (2013) Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Biochem. Soc. Trans. 41, 1048-1054
49. Cowan-Jacob, S.W., Jahnke, W. and Knapp, S. (2014) Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med. Chem. 6, 541-561